The global antifungal drugs market value was USD 14.8 billion in 2023, driven by the increasing prevalence of fungal infections across the globe. The global antifungal drugs market share is anticipated to grow at a CAGR of 3.7% during the forecast period of 2024-2032 to achieve a value of USD 20.6 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on drug class, the azoles segment accounts for a significant share in the market and is anticipated to witness a considerable growth in the forecast period. Azoles are used to treat a wide range of conditions, including yeast infection, tinea versicolor, and athlete's foot, and are available in different formulations, such as capsules, lotions, and sterile IV solutions, among others. These drugs offer improved absorption and distribution properties with fewer side effects and less serious drug interactions.
These factors have been contributing to the growth of the segment. Over the forecast period, the rising demand for azoles in combination with other antifungal agents to treat systematic and superficial fungal infections is likely to be a major factor driving the market. In addition to this, the growing cases of candidemia, blastomycosis, systematic candidiasis, and ocular fungal infections, among others are likely to aid the segment growth in the coming years.
North America accounts for a significant market share in the antifungal drugs industry due to the improved healthcare infrastructure, rise in echinocandin resistance, and the growing cases of fungal infections in the region. The growing pharmaceutical industry and the presence of the leading companies in the region are supporting the market growth in North America. Moreover, the increasing commercialisation of drugs is expected to further contribute to the antifungal drugs industry growth in the region.
Antifungal drugs can be defined as a type of drug that helps eliminate fungal infection from the body with minimum toxic side effects. Antifungal drugs basically act against fungal pathogens and are used in the treatment of fungal infections.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on drug class, the market is segmented into:
On the basis of indication, the industry is divided into:
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global market for antifungal drugs is driven by the growing prevalence of fungal infections across the globe. The increasing consumption of unhealthy food, which might compromise the immune system, is likely to increase the risk of fungal infections, which, in turn, is expected to propel the demand for antifungal drugs. Furthermore, the rising geriatric population, which is more susceptible to fungal infections such as ringworm, candidiasis, and systematic mycosis, among others, is significantly contributing to the market growth.
Over the forecast period, the growing investments by the leading pharmaceutical companies to develop novel and more effective drugs for fungal diseases are anticipated to augment the market growth in the forecast period.
The report gives a detailed analysis of the following key players in the global antifungal drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Drug Class||
|Breakup by Indication||
|Breakup by Dosage Form||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Fungal Disease Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Fungal Disease Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Fungal Disease Epidemiology (2016-2031)
5.3 Europe Fungal Disease Epidemiology (2016-2031)
5.4 Asia-Pacific Fungal Disease Epidemiology (2016-2031)
5.5 Latin America Fungal Disease Epidemiology (2016-2031)
5.6 Middle East & Africa Fungal Disease Epidemiology (2016-2031)
6 Global Antifungal Drugs Market Overview
6.1 Global Antifungal Drugs Market Historical Value (2017-2023)
6.2 Global Antifungal Drugs Market Forecast Value (2024-2032)
7 Global Antifungal Drugs Market Landscape
7.1 Global Antifungal Drugs Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Antifungal Drugs Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Indication
7.2.3 Analysis by Distribution Channel
8 Antifungal Drugs Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Antifungal Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Antifungal Drugs Market Segmentation
11.1 Global Antifungal Drugs Market by Drug Class
11.1.1 Market Overview
126.96.36.199 Amphotericin B
11.2 Global Antifungal Drugs Market by Indication
11.2.1 Market Overview
11.3 Global Antifungal Drugs Market by Dosage Form
11.3.1 Market Overview
11.3.3 Cream & Ointments
11.4 Global Antifungal Drugs Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.5 Global Antifungal Drugs Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Antifungal Drugs Market
12.1 Market Share by Country
12.2 United States of America
13 Europe Antifungal Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
14 Asia Pacific Antifungal Drugs Market
14.1 Market Share by Country
15 Latin America Antifungal Drugs Market
15.1 Market Share by Country
16 Middle East and Africa Antifungal Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.5 South Africa
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
23 Supplier Landscape
23.1 Abbott Laboratories
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.2 GlaxoSmithKline PLC
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.4 Pfizer Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.5 BAYER AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.7 MERCK & CO., INC.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.8 ASTELLAS PHARMA, INC.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.9 SCYNEXIS INC.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
24 Global Antifungal Drugs Market- Distribution Model (Additional Insight)
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The antifungal drugs market was valued at USD 14.8 billion in 2023.
The market is expected to grow at a CAGR of 3.7% from 2024 to 2032 to reach a value of USD 20.6 billion by 2032.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major drivers of the market include rising population of the geriatrics, commercialisation of antifungal drugs, growing investments by the leading pharmaceutical companies, improved healthcare infrastructure, rise in echinocandin resistance, and growing pharmaceutical industry.
The growing prevalence of fungal infections and increasing consumption of unhealthy food are the key trends guiding the growth of the industry.
Azoles, echinocandins, polyenes, and allylamines, among others are the major drug classes of the market. Azoles is further divided into voriconazole, posaconazole, and isavuconazole (CRESEMBA), among others whereas echinocandins is sub-divided into caspofungin and micafungin (mycamine/ funguard), among others. Among these, polyenes are segmented into amphotericin (ambisome), among others while allylamines is segmented into terbinafine, among others.What are the different indications based on which the market is segmented?Dermatophytosis, aspergillosis and candidiasis, among others are the different indications based on which the market is segmented. Candidiasis is further segmented into invasive candidiasis, vulvovaginal candidiasis (VVC), and mouth/throat/esophageal candidiasis, among others.
The major players in the industry are Abbott Laboratories, GlaxoSmithKline PLC, Novartis AG, and Pfizer Inc., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.